Outset Medical (OM) Projected to Post Quarterly Earnings on Wednesday

Posted by Stanley Muller on Nov 2nd, 2026

Outset Medical (NASDAQ:OM – Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.64) per share and revenue of $31.40 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The business had revenue of $31.64 million during the quarter, compared to the consensus estimate of $28.97 million. On average, analysts expect Outset Medical to post ($3.81) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Outset Medical Stock Performance

Shares of Outset Medical stock opened at $4.03 on Monday. The stock has a fifty day simple moving average of $3.73 and a 200 day simple moving average of $4.16. The company has a market capitalization of $75.76 million, a P/E ratio of -0.99 and a beta of 1.93. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. Outset Medical has a 12-month low of $2.84 and a 12-month high of $13.28.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Weiss Ratings lowered shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

View Our Latest Research Report on OM

Outset Medical Company Profile

(Get Free Report)

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.